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significantly fewer breaks in the ellipsoid zone on optical co-
herence tomography (7 eyes, 29.1%, vs. tamoxifen: 14 eyes, 
53.8%, and vs. controls: 14 eyes, 53.8%,  p = 0.04 in both anal-
yses, Fisher exact test). Retinal crystalline deposits were sig-
nificantly more frequent in patients receiving estrogens (12 
eyes, 16.2%, vs. 2 eyes, 2.7%,  p = 0.003, Fisher exact test). No 
significant between-group differences were apparent with 
regard to other features of the phenotype (extent of retinal 
low reflective spaces, late hyperfluorescence on fluorescein 
angiography or retinal thickness).  Conclusions: Tamoxifen 
treatment does not seem to accentuate structural changes 
in patients with MacTel type 2. Treatment with estrogens 
may exhibit a neuroprotective effect as suggested by the de-
creased frequency of ellipsoid zone breaks in corresponding 
patients, although corroborative studies are warranted to 
confirm these exploratory data.  © 2017 S. Karger AG, Basel 
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 Abstract 
 Purpose: To investigate the influence of hormone therapy 
with tamoxifen or estrogens on morphological changes in 
macular telangiectasia (MacTel) type 2 patients as revealed 
clinically in multiple imaging modalities.  Methods: Patients 
with a history of tamoxifen or estrogen use were selected 
from the cohort of the MacTel Study. A race-, age- and best-
corrected visual acuity-matched group of MacTel partici-
pants not under hormone therapy served as the comparison 
group. The frequencies of typical features of the MacTel phe-
notype apparent in color fundus, red-free, fluorescein angio-
graphic and optical coherence tomographic images were 
graded and analyzed statistically.  Results: Thirty-nine Mac-
Tel patients were included in the analyses, of whom 13 were 
receiving tamoxifen, 13 estrogens and 13 patients no hor-
mone treatment. Patients treated with estrogens showed 
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 The list of all participating principal investigators and centers in the 
MacTel Study can be found in the Appendix. 
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 Introduction 
 Idiopathic macular telangiectasia (MacTel) type 2 is a 
bilateral, progressive retinal disease potentially leading to 
a loss of central vision  [1] . The pathogenesis and natural 
history of the disease have so far been poorly understood. 
Historically considered a vascular disease, more recent 
clinical and experimental evidence points to a hereditary 
cause and a neurodegenerative pathogenesis in which ret-
inal Müller cells may play a central role  [1–3] .
 Clinically, MacTel is characterized by vascular signs 
comprising telangiectatic vessels, dilated, right-angle 
veins, fluorescein leakage in the angiogram and poten-
tially secondary sub/intraretinal neovascularization  [4, 
5] , and by neurodegenerative signs including the pres-
ence of refractile crystals in the inner retina  [6] , a loss of 
retinal transparency in the parafoveal region (also exhib-
iting increased reflectivity to short wavelength light), 
midretinal hyperpigmented plaques, low-reflective intra-
retinal spaces, and a progressive outer retinal atrophy 
identified on optical coherence tomography (OCT) im-
ages as a break in the line attributed to the ellipsoid zone 
(EZ) of the photoreceptors  [1, 7] .
 Evidence of the role of estrogens in neurodegenerative 
disease has steadily increased in recent years. Estrogen-
mediated neuroprotective mechanisms in the retina have 
been suggested  [8, 9] , though evidence of the role of es-
trogens in the retina remains limited to date.
 Tamoxifen is a type II antiestrogen with mixed estro-
genic/antiestrogenic properties. It is used as adjuvant 
therapy for estrogen-dependent breast carcinoma. Ocu-
lar toxicity from tamoxifen is well documented and char-
acterized by bilateral superficial refractile deposits in the 
inner layers of the retina as well as foveal cystoid spaces 
apparent on OCT  [10] . These features resemble charac-
teristics observed in MacTel.
 The role of concomitant hormone therapy in influenc-
ing the natural history of MacTel type 2 has not been in-
vestigated so far. The purpose of the present study is to 
investigate the possible influence of hormone therapy 
(tamoxifen or estrogens) on clinical morphological 
changes in MacTel type 2 patients.
 Materials and Methods 
 Patients were selected from the cohort of the MacTel Study, an 
international multicenter prospective study of the phenotype and 
potential therapies of MacTel, based on a history of past or present 
use of tamoxifen or estrogen hormone replacement therapy.  Age-, 
race- and best-corrected visual acuity-matched MacTel type 2 pa-
tients not receiving hormone therapy were selected for a control 
group. Eyes with neovascularization or secondary fibrotic scars 
were excluded.
 Baseline characteristics and eligibility criteria for enrolment 
into the study have been published previously  [11] . The study pro-
tocol adhered to the tenets of the Declaration of Helsinki and was 
approved by the local institutional review/ethics committee of 
each participating site. Prior to enrolment in the study, written, 
informed consent was obtained from each participant following an 
explanation of the nature of the study.
 Medical and ocular history and lifestyle information were col-
lected using standardized questionnaires. Multimodal images in-
cluding stereoscopic color/red-free fundus photographs and fluo-
rescein angiograms were recorded digitally. Color and fluorescein 
angiography images were analyzed for the presence of character-
istics of MacTel (loss of retinal transparency, telangiectatic vessels, 
right-angled venules, retinal crystals and fluorescein leakage/stain-
ing) using image overlays of a grading grid according to the Inter-
national Classification for ARM/AMD protocol as described pre-
viously  [11, 12] .
 OCT was performed using Stratus TD-OCT devices (Carl Zeiss 
Meditec, Dublin, CA, USA). High-quality crosshair scans (signal 
strength >7) were analyzed for the presence, size, and location rel-
ative to the foveal center of inner and outer retinal low-reflective 
spaces, for the presence of an enlarged foveal depression, for the 
presence of a break in the EZ and for pigment migration into the 
midretina. Retinal thickness was assessed by subfield in scans ac-
quired using the “fast macular” thickness protocol.
 Statistical analyses were performed using GraphPad Prism ver-
sion 5.00 for Windows (GraphPad Software, San Diego, CA, USA). 
Demographic characteristics for the patients were summarized us-
ing descriptive statistics expressed in terms of means ± standard 
deviation or proportions. Between-group analyses for all clinical 
and imaging parameters were performed by 2-way analysis of vari-
ance for continuous and by the Fisher exact test for categorical 
variables. A  p value of 0.05 or less was accepted as statistically sig-
nificant. 
 Results 
 A total of 39 patients (78 eyes) were included in these 
analyses, characteristics of each group are presented in 
 Table 1 . Four out of the 78 eyes were excluded, 2 having 
fibrotic scars (2.6%) and the other 2 subretinal neovascu-
larization (2.6%).
 Crystalline deposits were seen significantly more often 
in patients receiving estrogens than in those not receiving 
estrogens (12 eyes, 16.2%, vs. 2 eyes, 2.7%,  p = 0.003, Fish-
er exact test). Patients receiving tamoxifen also demon-
strated more crystals than controls but the difference did 
not reach statistical significance (8 eyes, 10.8%,  p = 0.072, 
Fisher exact test). Crystals were seen at the level of the in-
ternal limiting membrane, outside the central subfield of 
the International Classification (IC) grid. Differences be-
tween groups in loss of retinal transparency, visible telan-
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giectatic vessels, or hyperfluorescence on fluorescein an-
giography were not statistically significant.
 Patients treated with estrogens showed EZ breaks less 
frequently compared with either other group (7 eyes, 
29.1%, vs. tamoxifen: 14 eyes, 53.8%, and vs. controls: 14 
eyes, 53.8%,  p = 0.04 in both analyses, Fisher exact test). 
No statistically significant differences were demonstrable 
in any other OCT characteristic investigated.
 Discussion  
 Initially, MacTel was considered a vascular disease; 
however, over the last few years it has become evident that 
photoreceptor loss is integral to the disease and it may 
now be considered a disorder of neuroglial origin  [2, 4, 
13] . Conceivably the vascular changes may be secondary 
to neuroglial disease, as has been recorded in animal 
models of photoreceptor degeneration and humans with 
retinitis pigmentosa  [5–10] . In recent years a compelling 
case has been put forward for the use of estrogens as pro-
tective agents against neurodegenerative disorders of the 
central nervous system  [14, 15] . Their role in influencing 
synaptic plasticity, brain development and memory is 
well established. Several studies have highlighted the po-
tential neuroprotective action of estrogens against dam-
age produced by acute and chronic injury to the adult 
brain  [16–18] . The cellular and molecular mechanisms 
implicated in these neuroprotective effects however ap-
pear to be complex  [19–21] .
 Controversy exists as to the precise role of estrogens 
that can both afford neuroprotection and precipitate 
ischemic cerebral incidents  [22, 23] .
 The potential of estrogens in providing neuroprotec-
tion to the retina is less well understood. Bovine and rat 
retinas have been shown to express estrogen receptors α 
and β throughout the retinal thickness  [19–21, 24, 25] , 
and estrogens have shown promise in influencing the nat-
ural history of retinitis pigmentosa, age-related macular 
degeneration and glaucoma as well as exercising neuro-
protective properties against ischemia-reperfusion injury 
in the context of transient retinal ischemia  [26–28] .
 On the other hand, tamoxifen has long been identi-
fied as causative of a crystalline retinopathy exhibiting 
macular cystoid changes on OCT distinct from those 
seen in cystoid macular edema  [10] . The pathogenesis of 
tamoxifen-induced retinal toxicity is unclear, it may act 
in vivo as an antagonist of glutamate transporters in ret-
inal pigment epithelial cells, as already demonstrated in 
vitro  [29] . A presumed increase in glutamate could ex-
plain the axonal degeneration observed in histopathol-
ogy specimens and the formation of crystalline deposits. 
Müller cell impairment may follow retinal neuron in-
jury resulting in atrophy and the formation of the opti-
cally empty spaces observed on OCT in the foveal area 
 [30] . On the other hand, it has been suggested that 
tamoxifen could afford a potential neuroprotective ef-
fect through, among other modes of action, free radical 
scavenging. The mixed estrogenic/antiestrogenic prop-
erties of tamoxifen could potentially explain its seem-
ingly contradictory actions of neuroretinal toxicity and 
neuroprotective effect.
 The present study in its exploratory nature aims to 
 investigate the possibility of a link between hormone 
therapy and any of the typical findings encountered on 
imaging in patients with MacTel type 2. The significantly 
lower frequency of EZ breaks visible on OCT in estrogen-
treated patients points to a potential beneficial effect of 
estrogens in reducing the rate of progression in MacTel 
type 2. A break in the EZ has close functional correlates, 
and increase in its area is an established measure of dis-
ease progression in MacTel  [31] . The presence of EZ 
breaks is clearly detectable even using TD-OCT that was 
available in the initial years of the MacTel Study, prior to 
the introduction of spectral domain technology.
 Crystalline deposits and the appearance of macular 
cystoid spaces on OCT are strikingly similar in both 
tamoxifen retinopathy and MacTel type 2. In this study, 
 Table 1.  Distribution by age, gender, and visual acuity of patients 
included in the analyses
Tamoxifen Estrogen 
HRT
Control
Patients (eyes), n 13 (26) 13 (26) 13 (26)
Gender (female/male) 11/2 13/0 11/2
Age at baseline, years
Mean ± SD 65.3 ± 11.4 65.1 ± 5.5 64.3 ± 8.6
Range 50 – 75 54 – 75 51 – 75
BCVA (letter score) 
Right eyes
Mean ± SD 70.5 ± 7.2 68.5 ± 7.9 67.5 ± 11.8
Range 39 – 86 50 – 78 42 – 87
Left eyes
Mean ± SD 69.0 ± 11.4 68.4 ± 10.0 67.7 ± 107
Range 50 – 88 44 – 81 50 – 84
Worse eye
Mean ± SD 63.5 ± 11.6 63.2 ± 8.3 61.7 ± 8.7
Range 39 – 86 44 – 72 42 – 75
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however no increased severity of imaging findings in pa-
tients with MacTel type 2 receiving tamoxifen could be 
identified rendering unlikely the possibility of cumulative 
retinal toxicity in these cases. The significance of in-
creased prevalence of crystalline deposits in patients re-
ceiving estrogens is rather difficult to interpret.
 A reasonable criticism on the use of natural estrogens 
as neuroprotectants relates to their feminizing properties 
that would be undesirable to male patients. The use of 
synthetic estrogen analogs would however circumvent 
such limitations allowing benefiting from their antioxi-
dant properties regardless of gender or health predisposi-
tions.
 Limitations of the present study reside in its explor-
atory nature, limited sample size, and the lack of random-
ization. Our findings are however encouraging and war-
rant further research to accrue information on the precise 
role of hormone therapy on the natural history of MacTel 
type 2.
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